In late October 2019, FDA approved elexacaftor/tezacaftor/ivacaftor and ivacaftor (Trikafta—Vertex Pharmaceuticals), the first triple-combination therapy to treat patients ages 12 years and older with at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, which is estimated to represent 90% of the cystic fibrosis (CF) population.
Cara Aldridge Young